e-learning
resources
London 2016
Monday, 05.09.2016
New and old therapies for chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach
Neil C. Barnes (London, United Kingdom), Salman H. Siddiqui, Ian Pavord, Neil C. Barnes, Sally Lettis, Alessandro Guasconi, Stefano Petruzzelli
Source:
International Congress 2016 – New and old therapies for chronic lung diseases
Session:
New and old therapies for chronic lung diseases
Session type:
Oral Presentation
Number:
1763
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Neil C. Barnes (London, United Kingdom), Salman H. Siddiqui, Ian Pavord, Neil C. Barnes, Sally Lettis, Alessandro Guasconi, Stefano Petruzzelli. LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach. Eur Respir J 2016; 48: Suppl. 60, 1763
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
QVA149 compared with salmeterol/fluticasone (SFC) on exacerbations and its correlation with baseline blood eosinophils: A pooled analysis of LANTERN and ILLUMINATE
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids.
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept